27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Deutsche Bank’s Gregg Gilbert suspending the rating and estimates for Valeant Pharmaceuticals Intl Inc (NYSE: VRX), citing the company’s plans to restate prior results, the delay in its 10-K filing, the removal of its prior guidance for 2016, and an ongoing Board investigation.
“We have long been skeptical of the VRX business model that had formerly depended heavily on fast-paced acquisitions, aggressive cost cutting, tax arbitrage, aggressive US price increases, and a heavy debt load,” analyst Gregg Gilbert wrote.
Valeant is now transitioning to becoming more of an “organic execution and de-leveraging story.” Therefore, it would become “increasingly important, if not crucial,” to be able to track the company’s financial performance, Gilbert mentioned.
Valeant’s shares have pulled back significantly, Gilbert said, while adding that the risk-reward profile of the stock “has become more interesting.”
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!